Answers are grounded in this paper and cite their sources.
infection (CDI) is an increasing cause of morbidity in children, with recurrent disease posing substantial therapeutic challenges. Antibiotic therapy remains the cornerstone of initial management; however, up to 30% of children experience recurrence, and those with underlying comorbidities face recurrence rates as high as 65%. Fecal microbiota transplantation (FMT) has demonstrated superior efficacy over antibiotics for recurrent CDI (rCDI) in adults and has emerged as the most effective available intervention for pediatric rCDI. In this review, we synthesize current evidence on FMT efficacy, microbiome changes, and safety in children with CDI. Data from large multicenter cohort studies demonstrate cure rates exceeding 80%, with comparable efficacy observed in high-risk subpopulations, including those with inflammatory bowel disease and immunocompromising conditions. Critical research gaps remain, including the absence of randomized controlled trials and limited long-term safety data in children. Despite demonstrated effectiveness, significant barriers limit FMT accessibility for children. The COVID-19 pandemic has substantially impacted availability, and current regulatory changes have further restricted access. The lack of FDA-approved live biotherapeutic products approved for CDI in children creates additional challenges. We critically examine the emerging pipeline of next-generation microbiome-based therapies and identify the steps required to ensure children with recurrent CDI have access to safe, effective, and approved treatments.
No takes yet. Share an insight, caveat, or question.
Nicholson et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: